NCT02755376View on ClinicalTrials.gov

Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

April 28, 2016

Study Completion Date

December 1, 2018

Conditions
Deficiency of Anterior Cruciate Ligament
Interventions
BIOLOGICAL

Cartistem(TM)

ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.

BIOLOGICAL

hyaluronic acid

ACL reconstruction and injection of hyaluronic acid under arthroscopy.

PROCEDURE

ACL reconstruction only

ACL reconstruction only without any injection under arthroscopy

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02755376 - Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell | Biotech Hunter | Biotech Hunter